Company research
Niagen Bioscience, Inc.
CIK 1386570Updated Sep 27, 2026
SecurityNAGE · NASDAQ · equity
Historical securities (1)
CDXC · OTC · equity · closed Mar 18, 2025Name history
ChromaDex Corp. · through Mar 10, 2025CODY RESOURCES, INC. · through Jun 24, 2008
NAGE price & chart
Loading TradingView…
NASDAQ:NAGE on TradingView ↗About the company
Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.
In the news
No coverage from other publishers is available.
Recent filings
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
424B5 filing
EFFECT filing
Submission of Matters to a Vote of Security Holders
Items 5.07
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 106,406,000Source | 68,278,000Source | 54,964,000Source | 54,057,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 5,660,000Source | 359,000Source | 510,000Source | 671,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | 44,500,000Source | 27,200,000Source | 20,300,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 9,741,000Source | — | — | 8,482,000Source |
| Inventory, NetUSD | — | 9,192,000Source | 14,525,000Source | 14,677,000Source |
| Assets, CurrentUSD | 96,806,000Source | 64,102,000Source | 49,534,000Source | 46,567,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,192,000Source | 1,730,000Source | 2,400,000Source | 3,523,000Source |
| Other Assets, NoncurrentUSD | 425,000Source | 368,000Source | 383,000Source | 497,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 29,873,000Source | 22,184,000Source | 26,508,000Source | 25,385,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 79,000Source | 77,000Source | 75,000Source | 74,000Source |
| Additional Paid in CapitalUSD | 240,991,000Source | 227,931,000Source | 218,845,000Source | 214,094,000Source |
| Retained Earnings (Accumulated Deficit)USD | -164,528,000Source | -181,910,000Source | -190,460,000Source | -185,493,000Source |
| Stockholders' Equity Attributable to ParentUSD | 76,533,000Source | 46,094,000Source | 28,456,000Source | 28,672,000Source |
| Liabilities and EquityUSD | 106,406,000Source | 68,278,000Source | 54,964,000Source | 54,057,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 19,919,000Source | 17,948,000Source | 20,622,000Source | 17,869,000Source |
| Operating Lease, Liability, CurrentUSD | 1,002,000Source | 982,000Source | 691,000Source | 680,000Source |
| Accounts Payable, CurrentUSD | 10,796,000Source | 8,526,000Source | 10,232,000Source | 9,679,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,815,000Source | 1,657,000Source | 2,563,000Source | 3,539,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 7,722,000Source | 7,817,000Source | 9,493,000Source | 7,337,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 6,067,000Source | 3,656,000Source | 4,751,000Source | 5,739,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in InventoriesUSD | 11,635,000Source | -5,333,000Source | -152,000Source | 1,076,000Source |
| Increase (Decrease) in Accounts PayableUSD | 2,270,000Source | -1,067,000Source | 553,000Source | -744,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 13,504,000Source | 12,109,000Source | 7,117,000Source | -15,098,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -292,000Source | -143,000Source | -143,000Source | -334,000Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | 251,000Source | — | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 6,916,000Source | 5,369,000Source | -90,000Source | 7,654,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 20,128,000Source | 17,335,000Source | 6,884,000Source | -7,778,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 64,788,000Source | 44,660,000Source | 27,325,000Source | 20,441,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 1,000Source | 1,000Source | 2,000Source | 1,000Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 173,000Source | 151,000Source | 158,000Source | 186,000Source |
| DepreciationUSD | 612,000Source | 663,000Source | 870,000Source | 869,000Source |
| Gain (Loss) on Disposition of Intangible AssetsUSD | 117,000Source | — | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -4,000Source | 19,000Source | 5,000Source | -7,000Source |
| Gain (Loss) Related to Litigation SettlementUSD | 2,000,000Source | — | — | — |
| General and Administrative ExpenseUSD | 27,057,000Source | 18,375,000Source | 24,983,000Source | 28,286,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | 0Source | 3,000Source | — |
| Income Tax Expense (Benefit)USD | 810,000Source | 305,000Source | — | — |
| Investment Income, InterestUSD | 2,127,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | 17,382,000Source | 8,550,000Source | -4,938,000Source | -16,540,000Source |
| Operating ExpensesUSD | 66,910,000Source | 53,860,000Source | 56,379,000Source | 61,425,000Source |
| Operating Lease, ExpenseUSD | 1,330,000Source | 1,314,000Source | 1,214,000Source | 1,281,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | 0Source | 7,747,000Source |
| Proceeds from Stock Options ExercisedUSD | 7,246,000Source | 5,432,000Source | — | 0Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 129,423,000Source | 99,597,000Source | 83,570,000Source | 72,050,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Operating Income (Loss)USD | 16,279,000Source | 7,726,000Source | -5,599,000Source | -18,628,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 18,192,000Source | 8,855,000Source | — | — |
| Income Tax Expense (Benefit)USD | 810,000Source | 305,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | 17,382,000Source | 8,550,000Source | -4,938,000Source | -16,540,000Source |
| Earnings Per Share, BasicUSD per share | 0.22Source | 0.11Source | -0.07Source | -0.24Source |
| Earnings Per Share, DilutedUSD per share | 0.2Source | 0.11Source | -0.07Source | -0.24Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 79,178,000Source | 75,929,000Source | 74,985,000Source | 69,729,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 85,436,000Source | 78,125,000Source | 74,985,000Source | 69,729,000Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 173,000Source | 151,000Source | 158,000Source | 186,000Source |
| Current Income Tax Expense (Benefit)USD | 810,000Source | — | — | — |
| Gain (Loss) Related to Litigation SettlementUSD | 2,000,000Source | — | — | — |
| General and Administrative ExpenseUSD | 27,057,000Source | 18,375,000Source | 24,983,000Source | 28,286,000Source |
| Gross ProfitUSD | 83,189,000Source | 61,586,000Source | 50,780,000Source | 42,797,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 18,218,000Source | — | — | — |
| Interest Income (Expense), NetUSD | — | — | 661,000Source | 3,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | 1,913,000Source | 1,129,000Source | — | — |
| Investment Income, InterestUSD | 2,127,000Source | — | — | — |
| Operating ExpensesUSD | 66,910,000Source | 53,860,000Source | 56,379,000Source | 61,425,000Source |
| Operating Lease, ExpenseUSD | 1,330,000Source | 1,314,000Source | 1,214,000Source | 1,281,000Source |
| Research and Development ExpenseUSD | 6,330,000Source | 6,016,000Source | 4,958,000Source | 4,826,000Source |
| Selling and Marketing ExpenseUSD | 35,506,000Source | 29,469,000Source | 26,438,000Source | 28,313,000Source |
| Selling ExpenseUSD | 11,257,000Source | 9,822,000Source | — | — |
Filing attachments
ex991-nagepressreleasexsha.htm · 8-K · 2026-03-19
EX-99.1 2 ex991-nagepressreleasexsha.htm EX-99.1 Document Exhibit 99.1 Niagen Bioscience Increases Share Repurchase Program to $20 Million LOS ANGELES - March 19, 2026 - Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Board of Directors has authorized an increase to the Company’s previously disclosed share repurchase program (the “Program”), raising the total aut…
Read attachment ↗ex992-nageearningspresen.htm · 8-K · 2026-03-04
EX-99.2 3 ex992-nageearningspresen.htm EX-99.2 ex992-nageearningspresen Niagen Bioscience, Inc. Earnings Presentation Fourth Quarter and Full Year 2025 Nasdaq: NAGE | March 4, 2026 2 This presentation and other written or oral statements made from time to time by representatives of Niagen Bioscience contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-loo…
Read attachment ↗ex991-nagepressreleasexref.htm · 8-K · 2026-02-26
EX-99.1 2 ex991-nagepressreleasexref.htm EX-99.1 Document Exhibit 99.1 Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction Divestiture streamlines operations and advances the Company’s strategy to fully exit non-core activities LOS ANGELES - Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today a…
Read attachment ↗ex991-nagepressreleasex122.htm · 8-K · 2025-12-22
EX-99.1 3 ex991-nagepressreleasex122.htm EX-99.1 Document Exhibit 99.1 Niagen Bioscience Acquires Core Nicotinamide Riboside (NR) Patent Portfolio from Queen’s University Belfast This acquisition establishes Niagen Bioscience as the sole owner of the most comprehensive and defensible intellectual property portfolio in the NAD+ industry LOS ANGELES - December 22, 2025 - Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on…
Read attachment ↗ex991-nagepressreleasexsha.htm · 8-K · 2025-11-06
EX-99.1 2 ex991-nagepressreleasexsha.htm EX-99.1 Document Exhibit 99.1 Niagen Bioscience Announces $10 Million Share Repurchase Program LOS ANGELES - November 6, 2025 - Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Board of Directors has approved a share repurchase program under which the Company is authorized to repurchase up to $10 million of outstanding comm…
Read attachment ↗ex991-niagenbiosciencebran.htm · 8-K · 2025-03-19
EX-99.1 4 ex991-niagenbiosciencebran.htm EX-99.1 Document Exhibit 99.1 ChromaDex Evolves into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ with Precision Science The rebrand celebrates the company’s clinically proven flagship patented nicotinamide riboside (NR) ingredient, Niagen, the most well-researched, efficient, high-quality, and legal NAD+ booster available [Caption: Niagen Bioscience’s state-of-the-art research and development facility in Longmont, CO, …
Read attachment ↗